Breast Cancer — Viva Defence

Long Case Viva Defence

The scenario

A 52-year-old postmenopausal woman presents with a self-detected 3 cm lump in the upper outer quadrant of the right breast. Triple assessment confirms a grade 3 invasive ductal carcinoma that is ER-negative, PR-negative, and HER2-positive (3+ by immunohistochemistry). Ultrasound shows one suspicious axillary node. Staging CT shows no distant metastases. She is offered neoadjuvant therapy with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). [1]

Opening statement (SASPOP)

"This is Mrs R, a 52-year-old postmenopausal woman presenting with stage IIA (T2 N1 M0) HER2-positive invasive ductal carcinoma of the right breast. The tumour is ER-negative, PR-negative, and HER2 3+, with one suspicious axillary node and no distant metastases on staging CT. Her main problems are: the HER2-positive breast cancer, which is best managed with neoadjuvant dual HER2 blockade (TCHP) to downstage the tumour, assess response, and treat micrometastatic disease; the axillary node, which will be addressed surgically after neoadjuvant therapy; the need for cardiac monitoring during HER2-targeted therapy; and the question of germline genetic testing given her age. My priorities are to commence neoadjuvant TCHP for 6 cycles with baseline and serial echocardiography, to plan surgery (breast-conserving if the tumour responds, otherwise mastectomy) with sentinel node biopsy, to implement the KATHERINE response-adapted adjuvant strategy — continuing trastuzumab if pathologic complete response, or switching to T-DM1 if residual disease — to complete 1 year of total HER2-directed therapy, and to assess her hereditary risk." [1]

Problem list (numbered, prioritised)

1. Stage IIA HER2-positive breast cancer — needs neoadjuvant dual HER2 blockade followed by surgery and response-adapted adjuvant therapy.
2. Axillary nodal involvement — will be surgically staged after neoadjuvant therapy (sentinel node biopsy or targeted axillary dissection).
3. Cardiac risk from HER2-targeted therapy — requires baseline and serial echocardiography.
4. Hereditary risk assessment — age 52 with HER2-positive disease; family history should be carefully assessed.
5. Psychosocial support — new cancer diagnosis, intensive treatment, body image concerns. [1]

Integrated management plan

Pillar 1 — Neoadjuvant TCHP: "This patient has HER2-positive disease over 2 cm with a node involved, which makes neoadjuvant therapy the standard. I would offer docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) for 6 cycles. The dual HER2 blockade — trastuzumab binding domain IV and pertuzumab binding domain II of the HER2 receptor — prevents dimerisation and is superior to trastuzumab alone, nearly doubling the pathologic complete response rate to 40 to 60 percent. The CLEOPATRA trial established the benefit of adding pertuzumab in the metastatic setting, and this was extended to neoadjuvant use [4]. The anthracycline-free TCHP regimen avoids the additive cardiotoxicity of sequential anthracycline and trastuzumab."

Pillar 2 — Cardiac monitoring: "I would arrange a baseline echocardiogram before starting therapy — the LVEF must be above 50 percent to proceed. Serial echocardiography every 3 months during therapy is mandatory. If the LVEF drops by 10 percentage points or below 50 percent, I would hold the HER2-directed antibodies, initiate an ACE inhibitor and beta-blocker, and recheck in 4 to 6 weeks. Trastuzumab-related cardiotoxicity is typically reversible, unlike anthracycline cardiotoxicity [4]."

Pillar 3 — Surgery after neoadjuvant therapy: "After 6 cycles of TCHP (approximately 18 weeks), I would reassess clinically and radiologically. If the tumour has responded well, breast-conserving surgery (wide local excision with sentinel node biopsy) may be feasible. If not, a mastectomy would be performed. For the axilla, if the node was clinically positive before treatment, a targeted axillary dissection (sentinel node biopsy plus removal of the previously marked positive node) is performed. Radiotherapy follows breast-conserving surgery — the EBCTCG showed that radiotherapy halves local recurrence and reduces breast cancer mortality [2]."

Pillar 4 — Response-adapted adjuvant therapy (KATHERINE): "After surgery, the pathologic response determines the adjuvant strategy. If she achieves a pathologic complete response — no residual invasive disease in the breast or nodes — she continues trastuzumab alone to complete 1 year of total HER2-directed therapy. The HERA trial established that 1 year is the standard; 2 years offers no additional benefit [4]. If she has residual invasive disease, she switches to T-DM1 (ado-trastuzumab emtansine) for 14 cycles. The KATHERINE trial showed this halves the risk of invasive recurrence or death compared with continuing trastuzumab (3-year invasive disease-free survival 88.3 percent versus 77.0 percent) [5]. This is now the standard of care."

Probing questions the examiner would ask

Q: What are the four intrinsic subtypes of breast cancer, and why do they matter? [1]

A: "The four subtypes are defined by the receptor profile. Luminal A — ER strongly positive, PR positive, HER2-negative, low Ki-67 — is the commonest and most favourable, treated with endocrine therapy alone. Luminal B — ER-positive but either HER2-positive or with high proliferation (Ki-67 over 20 percent) — is more aggressive, treated with endocrine therapy plus chemotherapy and HER2-targeted therapy if applicable. HER2-enriched — ER-negative, HER2-positive — is driven by ERBB2 amplification, historically the most aggressive but now highly treatable with trastuzumab and pertuzumab [4]. Triple-negative / basal-like — ER-negative, PR-negative, HER2-negative — is the most aggressive, tends to occur in younger women and BRCA1 carriers, and is treated with chemotherapy plus pembrolizumab (KEYNOTE-522) [6] and olaparib for BRCA carriers (OlympiA) [7]. The subtypes matter because they drive every systemic therapy decision — endocrine therapy for ER-positive, HER2-targeted therapy for HER2-positive, and immunotherapy and PARP inhibition for triple-negative."

Q: Why is 1 year the standard duration for trastuzumab, and what would you do if the patient developed cardiotoxicity? [1]

A: "The HERA trial compared 1 year versus 2 years versus observation of adjuvant trastuzumab after chemotherapy. One year of trastuzumab significantly improved disease-free and overall survival, and extending to 2 years offered no additional benefit but increased cardiac toxicity [4]. If the patient developed significant cardiotoxicity — defined as an LVEF drop of 10 percentage points or a fall below 50 percent, or symptomatic heart failure — I would hold trastuzumab (and pertuzumab), start guideline-directed heart failure therapy (ACE inhibitor and beta-blocker), and recheck the echocardiogram in 4 to 6 weeks. Trastuzumab cardiotoxicity is typically reversible, and if the LVEF recovers, trastuzumab can often be cautiously reintroduced with close monitoring. If the LVEF does not recover, I would discuss alternative HER2-directed strategies with the oncology team, weighing the cardiac risk against the substantial benefit of HER2-targeted therapy."

Q: How would your management differ if this were a triple-negative tumour? [1]

A: "For triple-negative breast cancer (TNBC), the management paradigm is fundamentally different because endocrine therapy and trastuzumab are ineffective. The standard neoadjuvant regimen would be pembrolizumab combined with platinum-taxane chemotherapy (paclitaxel plus carboplatin, then anthracycline-cyclophosphamide), followed by surgery and adjuvant pembrolizumab, based on the KEYNOTE-522 trial, which improved both pathologic complete response and event-free survival [6]. If she had residual disease after neoadjuvant therapy, capecitabine would be considered (based on the CREATE-X trial for TNBC with residual disease, which is distinct from the T-DM1 approach for HER2-positive residual disease). Additionally, I would offer germline BRCA testing — all TNBC diagnosed under 60 should be tested — and if positive, she would be eligible for adjuvant olaparib for 1 year, based on the OlympiA trial, which improved invasive disease-free survival from 77.1 percent to 85.9 percent at 3 years [7]. The BRCA result would also inform ovarian cancer risk management and cascade family testing."

Q: How do you decide between breast-conserving surgery and mastectomy? [1]

A: "The decision is based on tumour size relative to breast size, the ability to achieve clear margins, multicentricity, and patient preference. Breast-conserving surgery (wide local excision) is equivalent to mastectomy in survival, provided clear margins are achieved and whole-breast radiotherapy is delivered — the EBCTCG meta-analysis of over 10 800 women showed that radiotherapy after breast-conserving surgery halves the 10-year recurrence rate and reduces 15-year breast cancer mortality [2]. Mastectomy is indicated for large tumours (relative to breast size), multicentric disease, failure to achieve clear margins with BCS, known BRCA mutation (where contralateral risk-reducing mastectomy is also discussed), or patient preference. For this patient, neoadjuvant therapy may downsize the tumour sufficiently to enable breast-conserving surgery — one of the key advantages of the neoadjuvant approach."

Q: What is the role of the Oncotype DX assay, and when would you use it? [1]

A: "The Oncotype DX 21-gene recurrence score is a genomic assay used in ER-positive, HER2-negative, node-negative (and more recently, node-positive with 1 to 3 nodes) breast cancer to guide the decision about whether to add chemotherapy to endocrine therapy. The TAILORx trial demonstrated that for women with a recurrence score of 11 to 25, endocrine therapy alone is non-inferior to chemoendocrine therapy in the overall population, sparing approximately 70 percent of these women from unnecessary chemotherapy [1] />. However, women aged 50 or younger with a score of 16 to 25 may derive a small benefit from chemotherapy. A score of 0 to 10 indicates very low risk — endocrine therapy alone. A score over 25 indicates high risk — chemoendocrine therapy is recommended. The assay is not used in HER2-positive or triple-negative disease, where chemotherapy is always indicated regardless of the genomic score."

Communication and shared decision-making

"Mrs R, I want to explain what we have planned and why. Your breast cancer is a type called HER2-positive, which means the cancer cells have too much of a protein called HER2 on their surface. This type used to be the most aggressive form of breast cancer, but we now have very effective targeted therapies — antibodies that attach to the HER2 protein and stop the cancer from growing. The plan is to give you chemotherapy combined with two of these targeted drugs before surgery, to shrink the tumour and let us see how well the treatment is working. After about 4 months of treatment, we will operate to remove what remains, and then we will continue with targeted therapy — either the same drug or a stronger version, depending on how much cancer is left. The whole treatment will take about a year. I want to be honest about the side effects: the chemotherapy will cause hair loss, fatigue, and some numbness in your fingers and toes, and the targeted drugs can affect your heart, which is why we will check your heart function regularly with ultrasound. Most heart effects are temporary and reversible if we catch them early. We will support you throughout — a cancer nurse coordinator will be your main contact, and we can connect you with a psychologist and a wig service. I want you to know that the outlook for HER2-positive breast cancer has been transformed by these targeted therapies, and many women in your situation do very well." [1]

Short Case Discussion — Breast Examination

Instruction: "Examine this patient's breasts and comment on the relevant findings." [1]

Systematic examination routine

1. End of bed — observe for cachexia (advanced disease), pallor (anaemia), and obvious asymmetry, skin changes, or surgical scars. Look for radiation-induced skin changes (telangiectasia, fibrosis) if the patient has had prior radiotherapy.
2. Inspection — with the patient sitting upright and arms elevated: compare both breasts for symmetry, contour, skin changes (dimpling, peau d'orange, erythema), nipple retraction or inversion, and any visible masses. Inspect for Paget disease (eczematous nipple change).
3. Palpation — with the patient supine and the arm above the head: systematically palpate each breast quadrant and the axillary tail using the flat of the fingers. Describe any lump by site (clock position and distance from the nipple), size, shape, consistency (hard, firm, soft), surface (smooth, irregular), mobility (mobile, fixed, tethered to skin or chest wall), and tenderness.
4. Nipple examination — check for discharge (note colour: clear, milky, bloody, serous), and express gently if indicated. Check for underlying masses.
5. Axillary examination — palpate the axillary nodes (central, anterior, posterior, lateral, apical groups) and the supraclavicular nodes. Assess for lymphoedema if the patient has had prior axillary surgery.
6. Completing the examination — examine the contralateral breast, assess for hepatomegaly (liver metastases), pleural effusion (lung metastases), and bone tenderness (if symptoms suggest bone metastasis). [1]

Key physical signs the patient demonstrates (for this case)

• A 3 cm hard, irregular, fixed mass in the upper outer quadrant of the right breast (the commonest site for breast cancer).
• Right axillary lymphadenopathy (one palpable node, mobile).
• No skin changes or nipple retraction (early presentation). [1]

Presentation template

"I examined Mrs R, a 52-year-old woman who appears well at the end of the bed. On inspection of the breasts with arms elevated, there is slight asymmetry with the right breast appearing fuller in the upper outer quadrant. There is no peau d'orange, no skin dimpling, and no nipple retraction or discharge. On palpation with the patient supine, there is a 3 cm hard, irregular mass in the upper outer quadrant of the right breast at the 10 o'clock position, 3 cm from the nipple. It is fixed to the surrounding tissue but not to the chest wall or skin, and is non-tender. The left breast is unremarkable. In the right axilla, there is one palpable mobile lymph node approximately 1.5 cm in diameter. There is no supraclavicular lymphadenopathy. These findings — a hard irregular fixed breast mass with axillary lymphadenopathy — are consistent with a breast malignancy. I would like to arrange triple assessment: bilateral mammography and breast ultrasound with core needle biopsy of the mass and the axillary node, and I would check the receptor status (ER, PR, HER2) on the biopsy." [1]

Discussion questions

Q: What is triple assessment, and why is it the diagnostic standard? [1]

A: "Triple assessment is the combination of clinical examination, imaging (mammography and/or ultrasound), and pathological assessment (core needle biopsy) of a breast lesion. It has a sensitivity of over 99 percent for breast cancer and is the gold standard for evaluating any palpable breast abnormality or suspicious imaging finding. Each component addresses a different dimension: examination characterises the clinical features, imaging defines the extent and radiological features, and biopsy provides the histological diagnosis and receptor status. The three components are concordant in the vast majority of cases — if any one is suspicious, the lesion is managed as malignant regardless of the others." [1]

Q: How is HER2 status determined, and what do you do with an equivocal result? [1]

A: "HER2 status is determined by immunohistochemistry (IHC) on the core biopsy. IHC 3+ (complete, intense membranous staining in over 10 percent of tumour cells) is positive — the patient is eligible for HER2-targeted therapy. IHC 0 is negative. IHC 1+ is weakly positive but considered HER2-low (relevant for trastuzumab deruxtecan in the metastatic setting). IHC 2+ is equivocal and requires confirmatory testing with in situ hybridisation (ISH) for ERBB2 gene amplification. If ISH shows amplification, the tumour is HER2-positive; if not, it is HER2-negative. This two-step algorithm ensures that HER2-positive patients are accurately identified for targeted therapy and that HER2-negative patients are not exposed to unnecessary and potentially toxic therapy." [1]

Q: What surveillance does a breast cancer survivor need? [1]

A: "For early-stage breast cancer treated with curative intent, surveillance aims to detect local or regional recurrence (which may be curable) and contralateral breast cancer. The standard programme is: clinical review every 6 to 12 months for 5 years then annually; annual mammography of the conserved and contralateral breast (starting 6 to 12 months after radiotherapy). Routine blood tests (liver function, tumour markers) and imaging (CT, bone scan) are NOT recommended for asymptomatic women with early-stage disease — they do not improve survival and increase false positives, anxiety, and cost. However, symptoms (new bone pain, breathlessness, jaundice, neurological symptoms) must be investigated promptly with targeted imaging. For higher-risk patients (stage III, triple-negative, HER2-positive), a lower threshold for imaging is appropriate. Survivorship care also addresses late effects: cardiac monitoring after anthracycline or trastuzumab, bone health on aromatase inhibitors, lymphoedema management, psychosocial support, and cardiovascular risk factor management — cardiovascular disease is the leading cause of death in long-term breast cancer survivors." [1]

Q: When should a breast cancer patient be referred for genetic testing? [1]

A: "Germline genetic testing should be offered to: any woman diagnosed under age 40; any woman with triple-negative breast cancer under 60; any woman with bilateral breast cancer; any man with breast cancer; any woman with a family history meeting referral criteria (two breast cancers under 50, breast plus ovarian cancer in the family, Ashkenazi Jewish ancestry with a breast cancer diagnosis, or a known BRCA mutation in the family). Testing is now done with multigene panel testing covering BRCA1, BRCA2, PALB2, TP53, CHEK2, and other genes. The result informs treatment (olaparib eligibility for BRCA carriers with HER2-negative disease), risk-reducing surgery (bilateral mastectomy, salpingo-oophorectomy), and cascade testing of family members." [1]